MiR-200a (osteosarcoma [86]), miR-200b (gastric cancer, oral squamous cell carcinoma, osteosarcoma [87,88]), miR-200c (prostate cancer [89,90]), and miR-429 (cervical cancer, osteosarcoma, thyroid cancer [91,92,93]) all target ZEB1/2 in different cancers. This evidence concerns the gene ZEB1 and gastric cancer.